Edgewise Therapeutics Guggenheim 3rd Annual Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Joining Guggenheim's 3rd Healthcare Innovation Conference. My name is Moritz. I am part of the therapeutics team, and it is my privilege today to host Kevin Koch, CEO of Edgewise Therapeutics. Kevin, thank you so much for making time for us. I want to jump right into your recent news. Last week, you published the design of your phase III program for obstructive and non-obstructive HCM. Could you just give us a brief overview of the trial design and the highlights?
Yeah. We had a very productive conversation with the FDA in regards to the trial design, and as you know, we published and presented data, the 12-week data on the drug class, and we also, this last quarter, talked about the mode of action of the drug. Let me give you a little bit of a highlight. The mode of action is highly differentiated from the cardiac myosin inhibitors. In fact, we target a regulatory protein which is within the lever arm of the sarcomere, which is the contractile element, and the CMIs bind directly to the ATPase, which binds directly to the actin filament. They affect the enzymatic activity. They can drive the contraction down to zero. Obviously, that has consequences for your heart when you eliminate all contraction.
We have a mechanism that regulates that contraction and changes the rate of that contraction by binding a regulatory subunit on the lever arm. That makes it a very different drug and the outcome very different when you are looking at endpoints like ejection fraction. That is data we put out. We published the paper. I think it is one of the It is a very nice paper on this mechanistic possibility. You also, in that paper, we showed that there are multiple different ways of interacting with the regulatory chain and that different ways provide different outcomes. In that paper, we showed that the enantiomer, so the mirror image of EDG-7500, EDG-7499, looks almost exactly like a CMI. We had exquisite control of the pharmacology by small changes in chemical structure. Okay? How is that translated to the clinic?
In June, we reported that under multiple different measures, we did not decrease ejection fraction, and what we showed, and we showed the FDA this, the PK versus the PD versus and so the concentration of the drug relative the effect on the systolic endpoints. We saw no relationship with over now, I think, 1,000 different measures. No relationship with the concentration of drug relative the ejection fraction and multiple ejection fraction-like measures of systolic function. The question is, and what is the challenge for the CMIs in hypertrophic cardiomyopathy, is that what you have seen is a dose and concentration-related decrease in ejection fraction with those drugs. That has led to a REMS and a boxed warning for heart failure, and has limited their ability to have uptake into the community cardiologist because of the need for repetitive echoes to keep the drug safe.
Now, they are highly efficacious drugs, no doubt about it, but that is a significant liability, and what it does is cap the utilization of the drug in the market. We think that that caps the market into perhaps, let's say, $2 billion or $3 billion, whereas if you look at the number of HCM patients, there are, say, 200,000 symptomatic patients, you could have a much broader market if you could move the drug into the community cardiologist community, right? We think that this mechanism has that possibility. What we put out last Thursday was, with our conversations with the FDA, we requested not to have any monitoring of the patients to get to the target dose, which is 150 milligrams. What we asked was allow the PI or allow the physician to determine what is the appropriate dose for each individual patient.
That was accepted by the agency. If you remember back in June, we had an initial conversation with the agency in the March timeframe, and they said that our original design was reasonable, but they wanted to see more data. We gave them the additional data. It, in our minds, remained reasonable, and that we could move the drug up to the target dose based on tolerability. That was a very important win for the company. We had a lot of discussions with the agency. In fact, I would say we had no discussions about more monitoring. We had discussions about how do you define tolerability, and also instead of stopping at the low dose when the patients have benefit, maybe how do you get them to a higher dose so that you really see effects on things like peak VO2?
That leads me to the next response of what else was in the press release. We had proposed, and I have said this to some of the investors, a Z-score, which is basically a composite of the peak VO2 and VE/VCO2. That is a I think we could drive greater power. We think that might be a more representative endpoint for benefit. From what the agency spoke to us, basically, it would be hard to interpret and say what number equals what efficacy level. We decided to measure them separately, and by measuring them separately, we ended up taking our conversations with the EMA and with the Japanese Regulatory Agency, is that they both preferred peak VO2 as a primary endpoint.
The agency also preferred peak VO2 as primary endpoint and allow things like KCCQ, other functional measures, and things like VE/VCO2 to be measured as secondary endpoints and looked at separately.
That was after trying. You have to try and coordinate three different regulatory agencies simultaneously to get them all in line. That was the lowest common denominator of everyone really wanted peak VO2 and believed in peak VO2. That is how we got to peak VO2 as the primary endpoint. I think that was important. The third important part of this protocol was we had originally thought that we could run one trial and use the statistical analysis plan to essentially take both populations into account and drive a p-value and a powering calculation off of that 600-patient trial. The agency preferred and told us directly that they would like to see statistical significance in both the non-obstructive and an isolated obstructive HCM population.
What that means is, if I have to hit stat sig on both, I might as well run them as separate trials under essentially an umbrella protocol. We have one protocol, you have one interaction with a site, and this is all kind of the sausage-making in running a clinical trial, but you have one interaction with the site. People come in, they can be funneled off into obstructive or funneled into non-obstructives. There are two separate trials that are powered for each individual trial. That actually was, I think, much more popular within the investment community. It made a lot more sense. I think it is cleaner. There is the need of perhaps increasing the N with that study. Maybe the other fourth important point in that press release was that we have engineered into the protocol an adaptive design.
We wanted to be able to expand the study based on if we see efficacy. It is almost like a futility analysis. If we see any efficacy, we will probably increase the Ns of, in particular, probably the non-obstructives. If you look at the obstructives, it is possible that you only need about 200 patients to actually get stat sig in that population. If everything goes in the right direction in non-obstructive, we could save perhaps six months. It gives us this opportunity to get real data on the variability of the trial results and also the actual magnitude of the clinical differential. You can now readjust your sizing based on real data instead of guessing.
As many of you know, we did not measure peak VO2 in our phase II study, so we are really going off of our NT-proBNP and some other parameters and what we see in KCCQ. We are also going off of the preclinical data, where we seem to have a greater cardiac reserve for this mechanism relative to CMIs. That is a long-winded answer to your question.
Well, it made my job a lot easier. You answered a lot of the questions I was about to ask. Maybe one point I wanted to focus on, you touched on this already briefly, is the titration based on tolerability.
How is that going to work in practice?
In practice, the patient will come in. They will be asked different questions. We do a New York Heart Association, or we do a question, for instance. It is different for each patient, but you ask them a question like, "If you can go up a stairs, how do you feel? Are you short of breath?" Or, "How do you feel during the day? Are there any side effects? Do you have any?" They will go through perhaps whatever they normally go through with their typical patient in this space. If they feel better, we have, in the protocol, said, "Then you should go up to the next dose, even if you feel good at that dose, because the efficacy is dose-responsive." We also showed that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
